Nidhi Saha

Nidhi Saha

BDS Dentistry

I am a medical content writer and editor. My interests lie in public health awareness and medical communication. I have worked as a clinical dentist and as a consultant research writer in an Indian medical publishing house. It is my constant endeavor is to update knowledge on newer treatment modalities relating to various medical fields. I have also aided in proofreading and publication of manuscripts in accredited medical journals. I like to sketch, read and listen to music in my leisure time.

Articles from Nidhi

Study evaluates the presence of the SARS-CoV-2 spike protein in urine samples collected during the COVID-19 pandemic

Study evaluates the presence of the SARS-CoV-2 spike protein in urine samples collected during the COVID-19 pandemic

Study says duplilumab reduces mortality from COVID-19

Study says duplilumab reduces mortality from COVID-19

BNT162b2 booster vaccine provides equal protection against BA.1 and BA.2

BNT162b2 booster vaccine provides equal protection against BA.1 and BA.2

Researchers discover a cell plasticity and inflammation driving druggable copper-signaling pathway

Researchers discover a cell plasticity and inflammation driving druggable copper-signaling pathway

SARS-CoV-2 nucleocapsid protein linked to COVID-19 severity

SARS-CoV-2 nucleocapsid protein linked to COVID-19 severity

Study finds low-risk of spillover SARS-CoV-2 infection from domestic cats

Study finds low-risk of spillover SARS-CoV-2 infection from domestic cats

Tuberculosis infection protects mice against COVID-19

Tuberculosis infection protects mice against COVID-19

Study finds fractionation of sulfated galactan from red alga can isolate its anti-SARS-CoV-2 properties

Study finds fractionation of sulfated galactan from red alga can isolate its anti-SARS-CoV-2 properties

SARS-CoV-2 nanobody that binds to the receptor-binding domain could prevent  COVID-19 in animals

SARS-CoV-2 nanobody that binds to the receptor-binding domain could prevent COVID-19 in animals

SARS-CoV-2 Delta variant-induced antibody response largely focuses on class 1 and 2 antibody epitopes

SARS-CoV-2 Delta variant-induced antibody response largely focuses on class 1 and 2 antibody epitopes

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.